Results of the TARGET All Comer (AC) clinical trial will be released at annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR; 16-19 May, Paris, France). Optical coherence tomography (OCT) sub-study primary endpoint three-month data will be presented at the conference.
TARGET AC is designed to assess the safety and efficacy of Firehawk rapamycin target-eluting coronary stent for the treatment of atherosclerotic coronary lesions in an all-comer, real-world population. All patients enrolled in the clinical trial have been randomised 1:1 to receive Firehawk or Abbott’s Xience family of drug-eluting stents. The clinical trial’s primary endpoint is the target lesion failure rate at 12 months. Patients will be followed up for five years post study enrolment.
Firehawk is the 3rd generation of MicroPort’s internally-developed, drug-eluting stent product family and offers a stent groove design. These grooves are intended to act as depository wells containing the polymer and drug combination, allowing Firehawk to have a targeted release of the drug to the coronary vessel wall. In addition, in patients with complex lesions and complex percutaneous coronary intervention technique, Firehawk is designed to overcome concerns with the durability of the polymer coating in conventional drug-eluting stents.
The TARGET AC clinical trial met its objective to recruit and enroll a total of 1,656 patients in 10 months, which was ahead of plan. The first patient for the TARGET AC clinical trial was enrolled in December 2015 by Lene Holmvang, Rigshospitalet University Hospital, Copenhagen, Denmark. Niels van Royen of VU University Medical Center (VUmc), a university hospital affiliated with the VU University Amsterdam, in The Netherlands, enrolled the final TAGET AC patient.